Literature DB >> 21029966

Future vaccination strategies against tuberculosis: thinking outside the box.

Stefan H E Kaufmann1.   

Abstract

With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and development is finally reaping the first fruits of its labors. Vaccine candidates in clinical trials may prevent TB disease reactivation by efficiently containing the pathogen Mycobacterium tuberculosis (Mtb). Future research should target vaccines that achieve sterile eradication of Mtb or even prevent stable infection. These are ambitious goals that can be reached only by highly cooperative engagement of basic immunologists, vaccinologists, and clinical researchers--or in other words, by translation from basic immunology to vaccine research and development, as well as reverse translation of insights from clinical trials back to hypothesis-driven research in the basic laboratory. Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029966     DOI: 10.1016/j.immuni.2010.09.015

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  69 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

2.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination.

Authors:  Chiara Nembrini; Armando Stano; Karen Y Dane; Marie Ballester; André J van der Vlies; Benjamin J Marsland; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

3.  Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors:  Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

4.  Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens.

Authors:  Pål Johansen; Antonia Fettelschoss; Beat Amstutz; Petra Selchow; Ying Waeckerle-Men; Peter Keller; Vojo Deretic; Leonhard Held; Thomas M Kündig; Erik C Böttger; Peter Sander
Journal:  Clin Vaccine Immunol       Date:  2011-04-06

5.  Tuberculosis vaccines--a new kid on the block.

Authors:  Stefan H E Kaufmann
Journal:  Nat Med       Date:  2011-02       Impact factor: 53.440

Review 6.  Tuberculosis: Is the landscape changing?

Authors:  Sutapa Khatua; Abby M Geltemeyer; Anand Gourishankar
Journal:  Pediatr Res       Date:  2016-10-10       Impact factor: 3.756

Review 7.  Beyond empiricism: informing vaccine development through innate immunity research.

Authors:  Stuart M Levitz; Douglas T Golenbock
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

8.  National and international policies to mitigate disease threats.

Authors:  Christopher Dye
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-10-19       Impact factor: 6.237

9.  A 2020 vision for vaccines against HIV, tuberculosis and malaria.

Authors:  Rino Rappuoli; Alan Aderem
Journal:  Nature       Date:  2011-05-26       Impact factor: 49.962

10.  Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Authors:  Jiuling Wang; Yaqing Qie; Wei Liu; Honghai Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.